BioLife Solutions Introduces the CellSeal CryoCase™ at International Society for Cell & Gene Therapies (ISCT) Conference in Vancouver
BioLife Solutions (NASDAQ: BLFS) introduced the CryoCase, a new addition to its CellSeal product line at the ISCT Conference in Vancouver. The CryoCase is designed for cell and gene therapy (CGT) primary packaging, aiming to replace cryopreservation bags with a fracture-resistant, rigid construction. It supports both manual and automated, closed-system use.
Available for demonstration at the ISCT event and expected to release to CGT developers in August, the CryoCase offers volume versatility, structural rigidity, and fill/retrieval port designs. It complies with USP 790 and USP 1790 standards and has shown high resistance to leaks and fractures during drop tests.
Early user tests indicated CryoCase may reduce particulates in single-use disposable manufacturing, potentially improving cell viability and recovery. Compatible with BioLife's Signata CT-5 system, CryoCase is expected to lower risks and costs in CGT manufacturing.
- Introduction of CryoCase targeting a growing CGT market.
- Designed to reduce particulates in drug products, improving quality.
- Fracture-resistant and rigid construction enhancing safety and reliability.
- Supports both manual and automated closed-system use.
- Complies with USP 790 and USP 1790 standards for visual inspection.
- High resistance to leaks and fractures, as shown in drop tests.
- Potentially reduces risks and costs in CGT manufacturing.
- Early user tests show improved cell viability and recovery.
- New product introduction without sales data or revenue forecasts.
- No detailed financial impact or cost-benefit analysis provided.
- Potential initial costs and required system integrations for users.
- Dependence on successful adoption by CGT developers.
Insights
The introduction of BioLife Solutions' CryoCase signifies a noteworthy advancement in the realm of cell and gene therapy (CGT). This new, cryo-compatible rigid container promises to address a critical issue in the CGT space: the presence of particulates in drug products. By offering a fracture-resistant, rigid structure and compatibility with closed-system automation, the CryoCase could significantly enhance the efficiency and safety of CGT manufacturing processes.
From a clinical perspective, the reduction or elimination of particulates is a substantial improvement. Particulates can lead to adverse reactions in patients, potentially derailing clinical trials or resulting in unfavorable outcomes. This innovative container aligns with the USP 790 and USP 1790 standards for visible particulates, potentially boosting regulatory compliance and patient safety.
The versatility of the CryoCase in handling larger fluid volumes (up to 75mL) and its robustness against leaks or fractures during drop testing are particularly relevant. These features suggest a high degree of reliability for both research and commercial applications. Overall, this product could streamline CGT workflows, reduce contamination risks and improve therapeutic outcomes. The impact on the CGT industry could be profound, paving the way for more efficient and safer biopharmaceutical processes.
From a financial perspective, the introduction of CryoCase represents a potential growth catalyst for BioLife Solutions. The CGT sector is expanding rapidly, driven by increasing approvals of gene therapies and a robust pipeline of clinical trials. The CryoCase's unique features, such as its rigid structure, transparency and compatibility with existing systems, could make it a preferred choice among CGT developers, possibly leading to increased market share for BioLife Solutions.
The revenue potential for CryoCase is substantial, given the high demand for reliable and efficient CGT manufacturing tools. If early product evaluation feedback is indicative of wider market reception, this product could drive significant top-line growth. Moreover, the compatibility with BioLife's own Signata CT-5 system suggests potential for synergistic product sales, enhancing overall revenue streams.
However, it is essential to monitor the competitive landscape and adoption rates closely. The CGT market is highly competitive, with several companies developing innovative solutions. The success of CryoCase will depend on its ability to deliver on its promises of improved throughput, reduced particulates and streamlined procedures. Investors should watch for adoption rates post-release and any strategic partnerships that might emerge to bolster market penetration.
New container developed for the needs of cell and gene therapy (CGT) primary packaging to replace cryopreservation bags with a fracture resistant, rigid construction built for both manual use and closed-system automation.
Expected to be released to CGT developers in August, the CryoCase is available for demonstration at this week's ISCT event in
The CryoCase is the first ever cryo-compatible rigid container designed for closed-system fill and retrieval for larger volumes of fluid (<75mL). The container is transparent, enabling improved end user compliance with USP 790, USP 1790, and other international visible inspection methods, and manufactured under strict environmental and processing controls designed to limit common sources of particulates in single-use disposable manufacturing. Early user testing has shown comparable cell viability and recovery for multiple cell types compared to storage in existing bags and drop testing in a frozen state demonstrates high resistance to leaks or fractures. Initial testing indicates that the CryoCase may materially reduce or eliminate particulates inherent in cryopreservation bags.
"Particulates in reagent manufacturing and final drug product is a growing problem that we believe can be reduced with better primary containers and true, closed-system approaches to CGT manufacturing," stated Todd Berard, Chief Marketing Officer. "The CryoCase is compatible with various downstream processing systems including our Signata CT-5, and we believe it can reduce overall risks and costs involved in creating and distributing these lifesaving therapies."
CryoCase samples are now available for testing. Contact your BioLife Solutions representative for more information.
About BioLife Solutions
BioLife Solutions is a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage, and distribution. For more information, please visit www.biolifesolutions.com or follow BioLife on LinkedIn and X.
Media & Investor Relations
At the Company
Troy Wichterman
Chief Financial Officer
(425) 402-1400
twichterman@biolifesolutions.com
Investors
LHA Investor Relations
Jody Cain
(310) 691-7100
jcain@lhai.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/biolife-solutions-introduces-the-cellseal-cryocase-at-international-society-for-cell--gene-therapies-isct-conference-in-vancouver-302157508.html
SOURCE BioLife Solutions, Inc.
FAQ
What is BioLife Solutions' new CryoCase?
When will the CryoCase be available?
What are the benefits of the CryoCase?
Is the CryoCase compatible with existing systems?
What standards does the CryoCase comply with?
